Guselkumab further extends choice in psoriasis prescribing

Tremfya (guselkumab) is licensed for the treatment of moderate to severe plaque psoriasis in adults and is the first biologic to selectively target interleukin (IL)-23.

by Lisa Lytle
Tremfya is administered by sc injection at weeks 0 and 4 followed by a maintenance dose every 8 weeks. | BIOPHOTO ASSOCIATES/SCIENCE PHOTO LIBRARY
Tremfya is administered by sc injection at weeks 0 and 4 followed by a maintenance dose every 8 weeks. | BIOPHOTO ASSOCIATES/SCIENCE PHOTO LIBRARY

Sign in to continue

Sign In

Trouble signing in?

Reset password: Click here

Need help? Email us

Register

FREE

  • Limited free articles a month 
  • Free email bulletins

Register Now

Subscribe now

Benefits include:

  • Full site access
  • Subscriber exclusive content
  • Exclusive bulletins

Choose a package